

## AroCell Q3 - Developing well, but looking over long-term forecasts

Redeye continues to see good cost control and highlights that the low y/y sales growth can be partly explained by a shift in revenue recognition in Q3. While we argue that the company is developing well, we reconsider our long-term sales forecast (contingent on a US launch of UBC Rapid/TK210 ELISA) and make downward changes.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**AroCell Q3 - Developing well, but looking over long-term forecasts**